BridgeBio Oncology Therapeutics (BBOT) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Larimar Therapeutics (LRMR) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 41.7% versus a loss of 71.8%. Larimar Therapeutics is the larger company by market cap ($285.7 million vs $275.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | LRMR |
|---|---|---|
| Share price | $3.44 | $2.75 |
| Market cap | $275.80M | $285.68M |
| 1-day change | -1.71% | -1.08% |
| YTD return | -72.52% | -27.82% |
| 1-year return | -71.83% | -41.74% |
| 5-year return | — | -77.31% |
| EPS (TTM) | $-0.07 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $6.42 |
| 52-week low | $3.36 | $2.72 |
| Distance from 52-week high | -76.87% | -57.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +613.66% | +423.64% |
| Average volume | 471.17K | 1.32M |
| Shares outstanding | 80.17M | 103.88M |
| Employees | 88 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LRMR has outperformed BBOT by 30.1 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Healthcare · Biotechnology · 88 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Healthcare · Biotechnology · 71 employees
BBOT vs LRMR FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Larimar Therapeutics?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $285.68M compared with $275.80M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or LRMR?
LRMR returned -41.74% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.